Role of ErbB-1 in Initiation and Progression of Serous and Mucinous Ovarian Neoplasms: Immunohistochemical Study Using Tissue Microarray Technique
/ 0
- Details
- Category: Vol. 85, September 2017
- Hits: 460
Role of ErbB-1 in Initiation and Progression of Serous and Mucinous Ovarian Neoplasms: Immunohistochemical Study Using Tissue Microarray Technique, RABAB A.A. MOHAMMED and HEBA E.M. EL-DEEK
Abstract
Background: Aberrant expression of the ErbB-1 receptor was reported in ovarian carcinoma, however aberration of its expression during early stages of tumour carcinogenesis and progression have not been yet studied. The purpose of the current study was to assess immunohistochemical expression of ErbB-1 receptor in a spectrum of serous and mucinous ovarian neoplasms including benign, borderline, primary malignant neoplasms and their extraovarian implants.
Patients and Methods: Tissue microarray blocks from 150 formalin-fixed paraffin embedded ovarian tissue blocks were constructed (20 normal ovarian surface and fallopian epithelium, 65 cystadenomas, 10 borderline neoplasms, 30 malignant and 15 metastatic deposits). Tissues were stained with anti-ErbB-1; expression was scored using 0, 1, 2 or 3 system. Because normal ovary is negative for ErbB-1 staining, positive staining starting from score 1+ was considered aberrant expression. Positive staining was correlated with the clinico-pathological characteristics.
Results: The normal epithelium showed negative or weak occasional staining for ErbB-1. A significant gradual increase of ErbB-1 expression was seen with the progression from benign towards borderline to malignant tumours in both serous and mucinous neoplasms. However, overexpression (Score +3) was more frequent in mucinous (27%) than in serous carcinoma (5.5%). Significant association between ErbB-1 positive staining (Scores 1, 2 and 3) with the presence of tissue necrosis and with high grades serous carcinoma was detected.
Conclusion: ErbB-1 expression is more frequent in mu-cinous than in serous ovarian carcinomas and is associated with transition from benign to borderline to malignant pheno-type and with features of higher proliferating tumours. This finding indicates a possible role of ErbB-1 in tumour carcino-genesis and progression and is a further evidence for the possible benefit from anti-ErbB-1 targeted therapy in ovarian carcinoma.